Our ultimate goal is to develop targetable, injectable vectors for the delivery of therapeutic genes to specific cell populations for application to the treatment of cancer and other diseases. Targetable vectors based upon murine leukemia virus (MLV) vectors should have the ability to bind to restricted cell populations, while retaining the ability of MLV to catalyze the fusion of viral and cell membranes. We will build chimeric envelope proteins by replacing the receptor-binding sequences of MLV with segments of other proteins that are capable of binding to specific cell- surface proteins. The goal of this project is to understand the mechanisms by which MLV vectors bind and fuse with cells. We believe that increased knowledge of the relationship between binding and fusion will enable us to build chimeric envelope proteins that will allow retroviral vector particles to transduce cells at least as efficiently as the MLV vectors currently in use. Quantitative assays to measure the affinity of binding and its kinetics, and to measure the efficiency of fusion will be developed. They will be used to evaluate the consequences of making a series of site-directed changes in the binding domains of the ecotropic and amphotropic envelope proteins. These quantitative data should permit us to generate a map of the amino acids within the envelope that play direct roles in receptor binding and in catalyzing the process of membrane fusion. In doing so we should gain insight into how the binding of MLV to its receptor triggers membrane fusions. In doing so we should gain insight into how the binding of MLV to its receptor triggers membrane fusion. We plan to produce soluble monomeric receptor binding domains from the ecotropic and amphotropic envelope proteins, and use them to characterize the number and homogeneity of receptors for these viruses on a variety of cell types. We will provide the soluble amphotyropic and ecotropic envelope binding-domain proteins to our collaborator (David Eisenberg, UCLA) who will use them to try to determine their three-dimensional structures by X-ray diffraction.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA059318-06
Application #
6102898
Study Section
Project Start
1998-06-01
Project End
2000-11-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
6
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Perez, Omar D; Logg, Christopher R; Hiraoka, Kei et al. (2012) Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther 20:1689-98
Christodoulopoulos, Ilias; Droniou-Bonzom, Magali E; Oldenburg, Jill E et al. (2010) Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors. Retrovirology 7:4
Epand, Raquel F; Zhang, Yan-Liang; Mirzabekov, Tajib et al. (2008) Membrane activity of an amphiphilic alpha-helical membrane-proximal cytoplasmic domain of the MoMuLV envelope glycoprotein. Exp Mol Pathol 84:9-17
Rozenberg-Adler, Yanina; Conner, John; Aguilar-Carreno, Hector et al. (2008) Membrane-proximal cytoplasmic domain of Moloney murine leukemia virus envelope tail facilitates fusion. Exp Mol Pathol 84:18-30
Logg, Christopher R; Baranick, Brian T; Lemp, Nathan A et al. (2007) Adaptive evolution of a tagged chimeric gammaretrovirus: identification of novel cis-acting elements that modulate splicing. J Mol Biol 369:1214-29
Hiraoka, Kei; Kimura, Takahiro; Logg, Christopher R et al. (2007) Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. Cancer Res 67:5345-53
Weber, Erin L; Cannon, Paula M (2007) Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential. Hum Gene Ther 18:849-60
Kikuchi, Eiji; Menendez, Silvia; Ozu, Choichiro et al. (2007) Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors. Clin Cancer Res 13:4511-8
Hsu, Faye Yuan-yi; Zhao, Yi; Anderson, W French et al. (2007) Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro. Cancer Invest 25:240-8
Kikuchi, E; Menendez, S; Ozu, C et al. (2007) Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts. Cancer Gene Ther 14:279-86

Showing the most recent 10 out of 70 publications